Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

Source :: Legal Monitor Worldwide. December 11, 2019
Publication Year :: 2019
Abstract: Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304). RELIEF [...]

Subjects :: Medical research
Fibromyalgia
Cyclobenzaprine
Media executives
Company business management
Business, international
Law

Tools